Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Carfilzomib
Related studies linked through entity extraction aliases.
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
- Status
- COMPLETED
- Phase
- PHASE2
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Status
- TERMINATED
- Phase
- PHASE2
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
- Status
- TERMINATED
- Phase
- PHASE1
Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE2
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
- Status
- COMPLETED
- Phase
- PHASE1
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1